ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2012
At a glance
- Drugs Celecoxib (Primary) ; Etoposide (Primary) ; Thalidomide (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- Acronyms Angiocomb
- 27 Dec 2012 Additional lead trial centers identified as reported by ClinicalTrials.gov.
- 27 Dec 2012 Planned number of patients changed from 10 to 50 as reported by ClinicalTrials.gov.
- 27 Dec 2012 Planned end date changed from 24 Nov 2008 to 1 Dec 2013 as reported by ClinicalTrials.gov.